A Study of HB-202/HB-201 in People With Human Papilloma Virus 16-Positive Head and Neck Squamous Cell Cancer (HPV 16+ HNSCC)
Conditions: HPV16+ Squamous Cell Carcinoma Interventions: Drug: HB-200; Other: Placebo Sponsors: Memorial Sloan Kettering Cancer Center; Hookipa Biotech GmbH; Naveris Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2024 Category: Research Source Type: clinical trials
Patient Characteristics, Treatment Patterns, and Healthcare Resource Utilization of Metastatic Melanoma Patients
Conditions: Metastatic Melanoma Sponsors: Novartis Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 17, 2024 Category: Research Source Type: clinical trials
10-year Retrospective Study of Oral and Maxillofacial Squamous Cell Carcinoma
Conditions: HNSCC; AI; Radiomic; MRI Interventions: Diagnostic Test: The Resnet50 deep learning (DL) model Sponsors: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 16, 2024 Category: Research Source Type: clinical trials
App-based Recording and Optimization of the Nutritional Status in Patients With Head and Neck Tumors During and After Radio(Chemo)Therapy
Conditions: Squamous Cell Carcinoma of Head and Neck Interventions: Procedure: App Usage; Other: Standard of Care Sponsors: University of Erlangen-N ürnberg Medical School Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 16, 2024 Category: Research Source Type: clinical trials
Tirelizumab in Combination With Carboplatin and Polymeric Micellar Paclitaxel for Neoadjuvant Therapy in cN+ HNSCC
Conditions: Head and Neck Squamous Cell Carcinoma; Head and Neck Cancer; HNSCC; Head Cancer Neck Interventions: Drug: Carboplatin; Drug: Tislelizumab; Drug: Polymeric Micellar Paclitaxel; Procedure: Surgical Resection of Primary +/- Neck Dissection; Radiation: Post-operative radiation therapy Sponsors: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 16, 2024 Category: Research Source Type: clinical trials
PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, and Sabestomig in HNSCC
Conditions: Head and Neck Squamous Cell Carcinoma Interventions: Biological: Rilvegostomig; Biological: Volrustomig; Biological: Sabestomig; Biological: Pembrolizumab Sponsors: Presage Biosciences; AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 16, 2024 Category: Research Source Type: clinical trials
Exploring the Optimal Timing of Minimally Invasive Surgery for Esophageal Squamous Cell Carcinoma
Conditions: Time Interventions: Radiation: Neoadjuvant chemradiotherapy; Procedure: Minimally invasive esophagectomy Sponsors: Shanghai Zhongshan Hospital Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Radical Synchronous Chemoradiotherapy With DDP/5-FU and PD-1 for Non-metastatic Rectal Squamous Cell Carcinoma
Conditions: Rectal Squamous Cell Carcinoma Interventions: Combination Product: PD-1 and CRT Sponsors: Sixth Affiliated Hospital, Sun Yat-sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma
Conditions: Melanoma Interventions: Drug: Ipilimumab; Drug: Nivolumab Sponsors: University of Utah Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Conditions: Advanced Cancer; Advanced Solid Tumor; Melanoma; Metastasis; Pleural Mesothelioma; Renal Cell Carcinoma; MSI-High; Mismatch Repair Deficiency; Colorectal Cancer; Hepatocellular Carcinoma; Hepatocellular Cancer; Renal Cell Cancer; Kidney Cancer; Skin Cancer; Non Small Cell Lung Cancer; NSCLC; Anaplastic Lymphoma Kinase Genomic Tumor Aberrations; ALK Genomic Tumor Aberrations Interventions: Drug: Alintegimod; Drug: Ipilimumab; Drug: Nivolumab Sponsors: 7 Hills Pharma, LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
Saliva Testing for High-Risk Human Papillomavirus Infection Oral Cavity and Pharynx Cancer
Conditions: Oropharyngeal Squamous Cell Carcinoma; Human Papillomavirus Infection Interventions: Genetic: Pre-Radiation Dental Evaluation/Sample Collection; Other: Pre-Study Visit; Genetic: Oral Medicine Consultation Visit/Sample Collection Sponsors: Wake Forest University Health Sciences; InnoTech Precision Medicine Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
Single- vs Two-staged Excisions of Thin Melanoma
Conditions: Melanoma (Skin); Surgery Interventions: Procedure: Wise vs wide Sponsors: Vastra Gotaland Region; Stockholm Region; Region Skane; Region V ästerbotten; Region Örebro County; Blekinge County Council Hospital; Region Östergötland; Dalarna County Council, Sweden Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
A Study of ST-1898 for Unresectable or Metastatic Melanoma
Conditions: Unresectable or Metastatic Melanoma Interventions: Drug: ST-1898 tablets Sponsors: Beijing Scitech-Mq Pharmaceuticals Limited Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2024 Category: Research Source Type: clinical trials
STRatIfication of Vulvar SCC by HPV and p53 Status to Guide Excision
Conditions: Vulvar Squamous Cell Carcinoma Interventions: Procedure: Surgery; Other: Active Surveillance Sponsors: Canadian Cancer Trials Group; Australia New Zealand Gynaecological Oncology Group Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
Oropharynx (OPX) Biomarker Trial
Conditions: Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Metastatic Oropharyngeal Squamous Cell Carcinoma; Oropharyngeal Squamous Cell Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8; Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8 Interventions: Other: Non-Interventional Study Sponsors: Mayo Clinic Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
